董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Peter A. Kiener | 男 | Director | 74 | 19.34万美元 | 8.72 | 2026-03-01 |
| Frank Morich | 男 | Director | 72 | 7.65万美元 | 11.60 | 2026-03-01 |
| Jill Broadfoot | 女 | Director | 65 | 5.43万美元 | 未持股 | 2026-03-01 |
| Pamela D. Garzone | 女 | Director | 71 | 6.94万美元 | 8.88 | 2026-03-01 |
| Patrick Verheyen | 男 | Director | 66 | 7.69万美元 | 9.70 | 2026-03-01 |
| Pasha Sarraf | 男 | Chairman and Director | 56 | 8.81万美元 | 34.00 | 2026-03-01 |
| Jill Broadfoot | 女 | Director | 64 | 未披露 | 未持股 | 2026-03-01 |
| Usman Azam | 男 | President, Chief Executive Officer and Director | 58 | 118.56万美元 | 未持股 | 2026-03-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Colin G. Sandercock | 男 | Senior Vice President, General Counsel and Secretary | 69 | 59.92万美元 | 62.38 | 2026-03-01 |
| Lucinda Warren | 女 | Chief Financial and Business Officer | 57 | 80.12万美元 | 32.50 | 2026-03-01 |
| Daniel G. Baker | 男 | Interim Chief Development Officer | 75 | 未披露 | 未持股 | 2026-03-01 |
| Usman Azam | 男 | President, Chief Executive Officer and Director | 58 | 118.56万美元 | 未持股 | 2026-03-01 |
董事简历
中英对照 | 中文 | 英文- Peter A. Kiener
-
PeterA.Kiener于2016年3月加入我们的董事会。Kiener博士于2014年10月至2018年2月担任全球生物制药公司SucampoPharmaceuticals，Inc.“；Sucampo”；的首席科学官兼研究与开发主管。在加入Sucampo之前，Kiener博士自2013年以来担任Ambrx，Inc.的首席科学官，该公司是一家临床阶段的生物制药公司，专注于抗体药物偶联物的开发。从2009年到2013年，他曾担任Zyngenia公司（早期生物制药公司）的总裁兼联席创始人。Kiener博士拥有兰开斯特大学（University of Lancaster）化学学士学位和牛津大学（University of Oxford）生物化学哲学博士学位。
Peter A. Kiener joined board of directors in March 2016. Dr. Kiener served as the Chief Scientific Officer and Head of Research and Development of Sucampo Pharmaceuticals, Inc., or Sucampo, a global biopharmaceutical company, from October 2014 to February 2018. Prior to joining Sucampo, Dr. Kiener served as the Chief Scientific Officer of Ambrx, Inc., a clinical stage biopharmaceutical company foced on the development of antibody drug conjugates, from 2013 to 2014. From 2009 to 2013, he was President and co founder of Zyngenia Inc., an early stage biopharmaceutical company. From 2001 to 2009, he was head of Research and R&D at MedImmune, the biologics research and development arm of AstraZeneca. Dr. Kiener is currently also a member of the board of directors of Peptone Switzerland AG and Ensocell Therapeutics. Dr. Kiener was a member of the board of directors of Pieris Pharmaceuticals, Inc. from 2018 through 2024, iTolerance, Inc. from 2021 through 2024 and Tetragenetics Inc. from 2018 through 2022. Dr. Kiener holds a Bachelor's degree in chemistry from the University of Lancaster and a Ph.D. in biochemistry from the University of Oxford. - PeterA.Kiener于2016年3月加入我们的董事会。Kiener博士于2014年10月至2018年2月担任全球生物制药公司SucampoPharmaceuticals，Inc.“；Sucampo”；的首席科学官兼研究与开发主管。在加入Sucampo之前，Kiener博士自2013年以来担任Ambrx，Inc.的首席科学官，该公司是一家临床阶段的生物制药公司，专注于抗体药物偶联物的开发。从2009年到2013年，他曾担任Zyngenia公司（早期生物制药公司）的总裁兼联席创始人。Kiener博士拥有兰开斯特大学（University of Lancaster）化学学士学位和牛津大学（University of Oxford）生物化学哲学博士学位。
- Peter A. Kiener joined board of directors in March 2016. Dr. Kiener served as the Chief Scientific Officer and Head of Research and Development of Sucampo Pharmaceuticals, Inc., or Sucampo, a global biopharmaceutical company, from October 2014 to February 2018. Prior to joining Sucampo, Dr. Kiener served as the Chief Scientific Officer of Ambrx, Inc., a clinical stage biopharmaceutical company foced on the development of antibody drug conjugates, from 2013 to 2014. From 2009 to 2013, he was President and co founder of Zyngenia Inc., an early stage biopharmaceutical company. From 2001 to 2009, he was head of Research and R&D at MedImmune, the biologics research and development arm of AstraZeneca. Dr. Kiener is currently also a member of the board of directors of Peptone Switzerland AG and Ensocell Therapeutics. Dr. Kiener was a member of the board of directors of Pieris Pharmaceuticals, Inc. from 2018 through 2024, iTolerance, Inc. from 2021 through 2024 and Tetragenetics Inc. from 2018 through 2022. Dr. Kiener holds a Bachelor's degree in chemistry from the University of Lancaster and a Ph.D. in biochemistry from the University of Oxford.
- Frank Morich
-
Frank Morich，自2023年2月5日起担任本公司董事。Morich博士被任命为与Viewpoint合并有关的董事。莫里奇博士于2021年2月至2023年2月3日担任Viewpoint的董事会成员。他还曾在位于马萨诸塞州波士顿的CUE-Biopharma担任董事会成员，该公司致力于蛋白质疗法，自2018年8月起应用于免疫肿瘤学、自身免疫和潜在的抗病毒应用，并自2021年4月起担任董事长。莫里奇博士是位于瑞士楚格的Aphaia Pharma的执行主席，该公司是一家临床阶段的生物制药公司，致力于治疗和预防肥胖和糖尿病等代谢紊乱，他自2022年6月起担任该职位。Morich博士于2015年至2021年担任MorphoSys的董事会成员，2004年至2010年担任Innate Pharma的董事会成员，这两家公司都是临床阶段的生物技术公司，专门从事抗体开发。在专注于董事会服务之前，Morich博士曾于2011年至2014年担任全球制药公司武田制药的首席商务官，并于2010年至2011年担任其国际业务执行副总裁。2008年至2010年，莫里奇博士担任临床阶段药物开发公司NOXXON Pharma AG的首席执行官，2005年至2007年，担任国际体外诊断公司Innogenetics N.V.的首席执行官和董事会成员。在此之前，Morich博士曾在拜耳担任多个职位，拜耳是一家全球性的制药和生命科学公司，包括拜耳公司管理委员会成员、全球产品开发主管和研发主管。Morich博士拥有马尔堡大学的医学博士和博士学位，专攻免疫学，专注于单克隆抗体。在进入私营部门之前，他还曾是一名军医。
Frank Morich joined board of directors in July 2018 and served as Chairman from April 2020 to June 2025. Dr. Morich has served as a consultant in the life sciences and health care indtries since 2015. Since 2023, Dr. Morich has served on the board of Perspective Therapeutics, a clinical stage biopharmaceutical company. Dr. Morich was a member of the supervisory board of MorphoSys AG, a late stage, biopharmaceutical company, from 2015 to 2021. From 2011 to 2014, Dr. Morich served as Chief Commercial Officer at Takeda Pharmaceutical, a global pharmaceutical company, and from 2010 to 2011, he served as Executive Vice President International Operations at Takeda. From 2008 to 2010, Dr. Morich served as Chief Executive Officer of NOXXON Pharma AG, a clinical stage drug development company, and from 2005 to 2007 he served as Chief Executive Officer and member of the board of directors of Innogenetics N.V., an international in vitro diagnostics company. During 2004, Dr. Morich served as Chief Executive Officer and Chairman of the Executive Board of AM Pharma B.V., a clinical stage drug development company. Prior to that, Dr. Morich held several positions at Bayer, a global pharmaceutical and life sciences company, including member of the board of management of Bayer AG, head of global product development and head of research and development. Dr. Morich graduated in medical studies at the University of Marburg, Germany. - Frank Morich，自2023年2月5日起担任本公司董事。Morich博士被任命为与Viewpoint合并有关的董事。莫里奇博士于2021年2月至2023年2月3日担任Viewpoint的董事会成员。他还曾在位于马萨诸塞州波士顿的CUE-Biopharma担任董事会成员，该公司致力于蛋白质疗法，自2018年8月起应用于免疫肿瘤学、自身免疫和潜在的抗病毒应用，并自2021年4月起担任董事长。莫里奇博士是位于瑞士楚格的Aphaia Pharma的执行主席，该公司是一家临床阶段的生物制药公司，致力于治疗和预防肥胖和糖尿病等代谢紊乱，他自2022年6月起担任该职位。Morich博士于2015年至2021年担任MorphoSys的董事会成员，2004年至2010年担任Innate Pharma的董事会成员，这两家公司都是临床阶段的生物技术公司，专门从事抗体开发。在专注于董事会服务之前，Morich博士曾于2011年至2014年担任全球制药公司武田制药的首席商务官，并于2010年至2011年担任其国际业务执行副总裁。2008年至2010年，莫里奇博士担任临床阶段药物开发公司NOXXON Pharma AG的首席执行官，2005年至2007年，担任国际体外诊断公司Innogenetics N.V.的首席执行官和董事会成员。在此之前，Morich博士曾在拜耳担任多个职位，拜耳是一家全球性的制药和生命科学公司，包括拜耳公司管理委员会成员、全球产品开发主管和研发主管。Morich博士拥有马尔堡大学的医学博士和博士学位，专攻免疫学，专注于单克隆抗体。在进入私营部门之前，他还曾是一名军医。
- Frank Morich joined board of directors in July 2018 and served as Chairman from April 2020 to June 2025. Dr. Morich has served as a consultant in the life sciences and health care indtries since 2015. Since 2023, Dr. Morich has served on the board of Perspective Therapeutics, a clinical stage biopharmaceutical company. Dr. Morich was a member of the supervisory board of MorphoSys AG, a late stage, biopharmaceutical company, from 2015 to 2021. From 2011 to 2014, Dr. Morich served as Chief Commercial Officer at Takeda Pharmaceutical, a global pharmaceutical company, and from 2010 to 2011, he served as Executive Vice President International Operations at Takeda. From 2008 to 2010, Dr. Morich served as Chief Executive Officer of NOXXON Pharma AG, a clinical stage drug development company, and from 2005 to 2007 he served as Chief Executive Officer and member of the board of directors of Innogenetics N.V., an international in vitro diagnostics company. During 2004, Dr. Morich served as Chief Executive Officer and Chairman of the Executive Board of AM Pharma B.V., a clinical stage drug development company. Prior to that, Dr. Morich held several positions at Bayer, a global pharmaceutical and life sciences company, including member of the board of management of Bayer AG, head of global product development and head of research and development. Dr. Morich graduated in medical studies at the University of Marburg, Germany.
- Jill Broadfoot
-
吉尔·布罗德富特自2021年11月起担任Acelrx Pharmaceuticals，Inc.董事。Broadfoot女士目前担任aTyr制药公司首席财务官，自2018年7月起担任该职位。2017年1月至2018年7月，Broadfoot女士担任Emerald Health Pharmaceuticals Inc.和Emerald Health Bioceuticals Inc.的首席财务官，负责为总部位于美国的制药和生物制药实体建立业务，以及建立业务、公司治理、财务和会计以及投资者关系等职能。在加入Emerald Health之前，布罗德富特于2016年5月至2017年1月担任GW Pharmaceuticals副总裁兼美国公司财务总监。在GW Pharmaceuticals工作期间，她的职责包括建立美国的商业运营，并在公司业务从英国转移到美国时执行美国上市公司的财务和会计准则。在加入GW Pharmaceuticals之前，Broadfoot女士于2004年10月至2013年3月担任Vical Inc.的首席财务官，负责财务、投资者关系、制造、信息技术、人力资源和业务发展。在此之前，Broadfoot女士曾在DJO Global，Inc.担任多个职位，最近担任财务副总裁，并在安永会计师事务所担任审计经理。Broadfoot女士是上市生物制药公司Otonomy, Inc.的董事会成员。Broadfoot女士拥有圣迭戈州立大学工商管理和会计学学士学位，是一名注册会计师（非在职）。
Jill Broadfoot has served as director since November 2021. Ms. Broadfoot currently serves as the Chief Financial Officer of aTyr Pharma, Inc., a position she has held since July 2018. From January 2017 to July 2018, Ms. Broadfoot served as Chief Financial Officer of Emerald Health Pharmaceuticals Inc. and Emerald Health Bioceuticals Inc., where she was responsible for establishing operations for the U.S. based pharmaceutical and bioceutical entities as ll as the establishment of operations, corporate governance, finance and accounting and investor relations functions, among others. Prior to Emerald Health, Ms. Broadfoot served as Vice President, U.S. Corporate Controller at GW Pharmaceuticals, from May 2016 to January 2017. While at GW Pharmaceuticals, her responsibilities included establishing U.S. commercial operations and implementing U.S. public company financial and accounting standards in connection with the transfer of corporate operations from the U.K. to the U.S. Prior to joining GW Pharmaceuticals, Ms. Broadfoot served as Chief Financial Officer of Vical Inc., from October 2004 to March 2013, where she had oversight of finance, investor relations, manufacturing, information technology, human resces, and biness development. Prior to that, Ms. Broadfoot held vario positions at DJO Global, Inc., most recently as Vice President of Finance, and served as an audit manager at Ernst & Young LLP. Ms. Broadfoot is a member of the board of directors of Cue BioPharma, Inc., a publicly traded biopharmaceutical company. Ms. Broadfoot holds a B.S. in Biness Administration and Accounting from San Diego State University and is a Certified Public Accountant (Inactive). Ms. Broadfoot's financial and biness expertise, including her diversified background in finance, operations and biness development, provides her with the qualifications and skills to serve as a director. - 吉尔·布罗德富特自2021年11月起担任Acelrx Pharmaceuticals，Inc.董事。Broadfoot女士目前担任aTyr制药公司首席财务官，自2018年7月起担任该职位。2017年1月至2018年7月，Broadfoot女士担任Emerald Health Pharmaceuticals Inc.和Emerald Health Bioceuticals Inc.的首席财务官，负责为总部位于美国的制药和生物制药实体建立业务，以及建立业务、公司治理、财务和会计以及投资者关系等职能。在加入Emerald Health之前，布罗德富特于2016年5月至2017年1月担任GW Pharmaceuticals副总裁兼美国公司财务总监。在GW Pharmaceuticals工作期间，她的职责包括建立美国的商业运营，并在公司业务从英国转移到美国时执行美国上市公司的财务和会计准则。在加入GW Pharmaceuticals之前，Broadfoot女士于2004年10月至2013年3月担任Vical Inc.的首席财务官，负责财务、投资者关系、制造、信息技术、人力资源和业务发展。在此之前，Broadfoot女士曾在DJO Global，Inc.担任多个职位，最近担任财务副总裁，并在安永会计师事务所担任审计经理。Broadfoot女士是上市生物制药公司Otonomy, Inc.的董事会成员。Broadfoot女士拥有圣迭戈州立大学工商管理和会计学学士学位，是一名注册会计师（非在职）。
- Jill Broadfoot has served as director since November 2021. Ms. Broadfoot currently serves as the Chief Financial Officer of aTyr Pharma, Inc., a position she has held since July 2018. From January 2017 to July 2018, Ms. Broadfoot served as Chief Financial Officer of Emerald Health Pharmaceuticals Inc. and Emerald Health Bioceuticals Inc., where she was responsible for establishing operations for the U.S. based pharmaceutical and bioceutical entities as ll as the establishment of operations, corporate governance, finance and accounting and investor relations functions, among others. Prior to Emerald Health, Ms. Broadfoot served as Vice President, U.S. Corporate Controller at GW Pharmaceuticals, from May 2016 to January 2017. While at GW Pharmaceuticals, her responsibilities included establishing U.S. commercial operations and implementing U.S. public company financial and accounting standards in connection with the transfer of corporate operations from the U.K. to the U.S. Prior to joining GW Pharmaceuticals, Ms. Broadfoot served as Chief Financial Officer of Vical Inc., from October 2004 to March 2013, where she had oversight of finance, investor relations, manufacturing, information technology, human resces, and biness development. Prior to that, Ms. Broadfoot held vario positions at DJO Global, Inc., most recently as Vice President of Finance, and served as an audit manager at Ernst & Young LLP. Ms. Broadfoot is a member of the board of directors of Cue BioPharma, Inc., a publicly traded biopharmaceutical company. Ms. Broadfoot holds a B.S. in Biness Administration and Accounting from San Diego State University and is a Certified Public Accountant (Inactive). Ms. Broadfoot's financial and biness expertise, including her diversified background in finance, operations and biness development, provides her with the qualifications and skills to serve as a director.
- Pamela D. Garzone
-
Pamela Garzone，自2021年9月起担任Anixa Biosciences, Inc.的首席开发官，该公司专注于肿瘤学和传染病。在加入Anixa之前，Garzone博士曾于2019年5月至2021年5月在Scripps研究所的一个部门Calibr担任首席医疗官。从2009年5月到2019年5月，Garzone博士担任副总裁，集团资产团队负责人，在辉瑞公司专注于早期肿瘤临床研究。Garzone博士获得了普渡大学的药学学士学位和匹兹堡大学的药学实践硕士学位。Garzone博士在匹兹堡大学获得临床科学博士学位。
Pamela D. Garzone joined board of directors in April 2023. Dr. Garzone has served as the Chief Development Officer at Anixa Biosciences, Inc., a company foced on oncology and infectio diseases, since September 2021. Prior to joining Anixa, Dr. Garzone served as the Chief Medical Officer at Calibr, a division of the Scripps Research Institute from May 2019 to May 2021. From May 2009 through May 2019, Dr. Garzone served as the Vice President, Group Asset Team Lead foced on early oncology clinical research at Pfizer Inc. Dr. Garzone earned a B.S. degree in pharmacy from Purdue University and an M.S. in pharmacy practice from the University of Pittsburgh. Dr. Garzone received her Ph.D. in clinical science from the University of Pittsburgh. - Pamela Garzone，自2021年9月起担任Anixa Biosciences, Inc.的首席开发官，该公司专注于肿瘤学和传染病。在加入Anixa之前，Garzone博士曾于2019年5月至2021年5月在Scripps研究所的一个部门Calibr担任首席医疗官。从2009年5月到2019年5月，Garzone博士担任副总裁，集团资产团队负责人，在辉瑞公司专注于早期肿瘤临床研究。Garzone博士获得了普渡大学的药学学士学位和匹兹堡大学的药学实践硕士学位。Garzone博士在匹兹堡大学获得临床科学博士学位。
- Pamela D. Garzone joined board of directors in April 2023. Dr. Garzone has served as the Chief Development Officer at Anixa Biosciences, Inc., a company foced on oncology and infectio diseases, since September 2021. Prior to joining Anixa, Dr. Garzone served as the Chief Medical Officer at Calibr, a division of the Scripps Research Institute from May 2019 to May 2021. From May 2009 through May 2019, Dr. Garzone served as the Vice President, Group Asset Team Lead foced on early oncology clinical research at Pfizer Inc. Dr. Garzone earned a B.S. degree in pharmacy from Purdue University and an M.S. in pharmacy practice from the University of Pittsburgh. Dr. Garzone received her Ph.D. in clinical science from the University of Pittsburgh.
- Patrick Verheyen
-
Patrick Verheyen，于2015年至2021年在医疗保健产品公司强生担任杨森业务发展全球主管。Verheyen先生在此期间还担任杨森制药集团运营委员会成员。Verheyen先生于1986年加入强生，曾担任多个职务，包括2012年至2015年担任伦敦强生创新中心负责人。Verheyen先生在比利时佛兰德斯的鲁汶大学获得生物工程学位。
Patrick Verheyen joined board of directors in April 2023. Mr. Verheyen served as the Global Head of Janssen Biness Development at Johnson & Johnson, a healthcare products company, from 2015 through 2021. Mr. Verheyen also served as a member of the Janssen's Pharmaceuticals Group Operating Committee during this time. Mr. Verheyen joined Johnson & Johnson in 1986 and served in vario roles, including as Head of London Johnson & Johnson Innovation Center from 2012 through 2015. - Patrick Verheyen，于2015年至2021年在医疗保健产品公司强生担任杨森业务发展全球主管。Verheyen先生在此期间还担任杨森制药集团运营委员会成员。Verheyen先生于1986年加入强生，曾担任多个职务，包括2012年至2015年担任伦敦强生创新中心负责人。Verheyen先生在比利时佛兰德斯的鲁汶大学获得生物工程学位。
- Patrick Verheyen joined board of directors in April 2023. Mr. Verheyen served as the Global Head of Janssen Biness Development at Johnson & Johnson, a healthcare products company, from 2015 through 2021. Mr. Verheyen also served as a member of the Janssen's Pharmaceuticals Group Operating Committee during this time. Mr. Verheyen joined Johnson & Johnson in 1986 and served in vario roles, including as Head of London Johnson & Johnson Innovation Center from 2012 through 2015.
- Pasha Sarraf
-
Pasha Sarraf，自2023年起担任战略咨询公司Upupa Advisory的负责人。Sarraf博士此前曾在2021年至2023年期间担任生物技术公司Matterhorn Biosciences的首席执行官和执行董事会成员，在那里他建立了一个支持团队，并扩大了科学努力，以证明他们基于T细胞受体的平台的价值。在加入Matterhorn Biosciences之前，Sarraf博士曾于2020年至2021年担任风险投资公司Flagship Pioneering的运营合伙人。在那里，他带领旗舰Pioneering的投资组合公司的一个团队在帕金森病中发现了新的基因回路，启动了一个创新靶点的药物发现计划，该计划后来获得了GSK plc的许可。在加入Flagship Pioneering之前，Sarraf博士曾在Leerink Partners（前身为SVB Leerink）担任高级华尔街分析师和董事总经理。在此之前，Sarraf博士于2008年加入麦肯锡公司，担任过各种职务，包括从2015年到2018年担任生命科学实践的合伙人，在那里他专注于战略、勤奋和预测。Sarraf博士是生物技术公司PolarityBio和Praesidia Biotherapeutics的董事会成员，并担任董事长。Sarraf博士在哈佛医学院获得了医学博士学位，并在麻省总医院和美国国立卫生研究院接受了内科和风湿病学方面的培训，专注于血管炎、硬皮病和遗传炎症性疾病。
Pasha Sarraf joined board of directors in March 2025 and was appointed as Chairman in June 2025. Dr. Sarraf has served as Principal at Upupa Advisory, a strategic advisory firm, since 2023. Dr. Sarraf previoly served as the Chief Executive Officer and executive board member of Matterhorn Biosciences, a biotechnology company, from 2021 to 2023, where he built a supportive team and scaled the scientific effort to demonstrate the value of their T cell receptors based platform. Prior to joining Matterhorn Biosciences, Dr. Sarraf served as an Operating Partner of Flagship Pioneering, a venture capital company, from 2020 to 2021. There, he led a team at a portfolio company of Flagship Pioneering who discovered novel genetic circuits in Parkinson's Disease, initiating a drug discovery program for an innovative target that was later licensed by GSK plc. Prior to joining Flagship Pioneering, Dr. Sarraf served as Senior Wall Street Analyst and Managing Director at Leerink Partners, formerly SVB Leerink. Prior to that, Dr. Sarraf joined McKinsey & Company in 2008 and served in vario roles, including as Partner in the life sciences practice from 2015 through 2018, where he foced on strategy, diligence and forecasting. Dr. Sarraf is a member of the boards of directors of biotechnology companies PolarityBio and Praesidia Biotherapeutics, where he serves as Chairman. Dr. Sarraf obtained his M.D. and Ph.D. at Harvard Medical School and trained in internal medicine and rheumatology at Massachetts General Hospital and National Institutes of Health, focing on vasculitis, scleroderma and genetic inflammatory disorders. Dr. Sarraf has authored over 50 publications and multiple patents for novel therapies and molecular targets. - Pasha Sarraf，自2023年起担任战略咨询公司Upupa Advisory的负责人。Sarraf博士此前曾在2021年至2023年期间担任生物技术公司Matterhorn Biosciences的首席执行官和执行董事会成员，在那里他建立了一个支持团队，并扩大了科学努力，以证明他们基于T细胞受体的平台的价值。在加入Matterhorn Biosciences之前，Sarraf博士曾于2020年至2021年担任风险投资公司Flagship Pioneering的运营合伙人。在那里，他带领旗舰Pioneering的投资组合公司的一个团队在帕金森病中发现了新的基因回路，启动了一个创新靶点的药物发现计划，该计划后来获得了GSK plc的许可。在加入Flagship Pioneering之前，Sarraf博士曾在Leerink Partners（前身为SVB Leerink）担任高级华尔街分析师和董事总经理。在此之前，Sarraf博士于2008年加入麦肯锡公司，担任过各种职务，包括从2015年到2018年担任生命科学实践的合伙人，在那里他专注于战略、勤奋和预测。Sarraf博士是生物技术公司PolarityBio和Praesidia Biotherapeutics的董事会成员，并担任董事长。Sarraf博士在哈佛医学院获得了医学博士学位，并在麻省总医院和美国国立卫生研究院接受了内科和风湿病学方面的培训，专注于血管炎、硬皮病和遗传炎症性疾病。
- Pasha Sarraf joined board of directors in March 2025 and was appointed as Chairman in June 2025. Dr. Sarraf has served as Principal at Upupa Advisory, a strategic advisory firm, since 2023. Dr. Sarraf previoly served as the Chief Executive Officer and executive board member of Matterhorn Biosciences, a biotechnology company, from 2021 to 2023, where he built a supportive team and scaled the scientific effort to demonstrate the value of their T cell receptors based platform. Prior to joining Matterhorn Biosciences, Dr. Sarraf served as an Operating Partner of Flagship Pioneering, a venture capital company, from 2020 to 2021. There, he led a team at a portfolio company of Flagship Pioneering who discovered novel genetic circuits in Parkinson's Disease, initiating a drug discovery program for an innovative target that was later licensed by GSK plc. Prior to joining Flagship Pioneering, Dr. Sarraf served as Senior Wall Street Analyst and Managing Director at Leerink Partners, formerly SVB Leerink. Prior to that, Dr. Sarraf joined McKinsey & Company in 2008 and served in vario roles, including as Partner in the life sciences practice from 2015 through 2018, where he foced on strategy, diligence and forecasting. Dr. Sarraf is a member of the boards of directors of biotechnology companies PolarityBio and Praesidia Biotherapeutics, where he serves as Chairman. Dr. Sarraf obtained his M.D. and Ph.D. at Harvard Medical School and trained in internal medicine and rheumatology at Massachetts General Hospital and National Institutes of Health, focing on vasculitis, scleroderma and genetic inflammatory disorders. Dr. Sarraf has authored over 50 publications and multiple patents for novel therapies and molecular targets.
- Jill Broadfoot
-
Jill Broadfoot于2025年6月加入董事会。Broadfoot女士自2018年7月起担任临床阶段生物制药公司aTyr制药，Inc.的首席财务官。在加入aTyr制药之前，Broadfoot女士曾担任Emerald Health Pharmaceuticals Inc.和Emerald Health Bioceuticals Inc.的首席财务官，负责为美国的制药和生物医药实体建立运营，如建立运营、公司治理、财务和会计、信息技术和投资者关系职能等。在加入Emerald Health之前，Broadfoot女士曾担任GW Pharmaceuticals的副总裁兼美国公司财务总监，其职责包括建立美国商业运营、监督信息技术以及实施与公司业务从英国转移到美国相关的美国上市公司财务和会计准则。在加入GW Pharmaceuticals之前，Broadfoot女士曾担任Vical Inc.的首席财务官，负责监督财务、投资者关系、制造、信息技术、人力资源以及BINCE Development。在此之前，Broadfoot女士曾在DJO Global，Inc.担任多个职位，最近担任财务副总裁，并在Ernst & Young LLP担任审计经理。Broadfoot女士担任生物技术公司Talphera，Inc.的董事会成员。She Previoly曾在Otonomy，Inc.和Angiocrine Biosciences，Inc.的董事会任职，这两家公司都是一家生物技术公司。
Jill Broadfoot joined board of directors in June 2025. Ms. Broadfoot has served as Chief Financial Officer of aTyr Pharma, Inc., a clinical stage biopharmaceutical company, since July 2018. Prior to aTyr Pharma, Ms. Broadfoot served as Chief Financial Officer of Emerald Health Pharmaceuticals Inc. and Emerald Health Bioceuticals Inc., where she was responsible for establishing operations for the U.S. based pharmaceutical and bioceutical entities as ll as the establishment of operations, corporate governance, finance and accounting, information technology and investor relations functions, among others. Prior to Emerald Health, Ms. Broadfoot served as Vice President, U.S. Corporate Controller at GW Pharmaceuticals, where her responsibilities included establishing U.S. commercial operations, overseeing information technology, and implementing U.S. public company financial and accounting standards in connection with the transfer of corporate operations from the U.K. to the U.S. Prior to joining GW Pharmaceuticals, Ms. Broadfoot served as Chief Financial Officer of Vical Inc. where she had oversight of finance, investor relations, manufacturing, information technology, human resces, and biness development. Prior to that, Ms. Broadfoot held vario positions at DJO Global, Inc., most recently as Vice President of Finance, and served as an audit manager at Ernst & Young LLP. Ms. Broadfoot serves on the board of directors of Talphera, Inc., a biotechnology company. She previoly served on the board of directors of Otonomy, Inc. and Angiocrine Biosciences, Inc., both biotechnology companies. - Jill Broadfoot于2025年6月加入董事会。Broadfoot女士自2018年7月起担任临床阶段生物制药公司aTyr制药，Inc.的首席财务官。在加入aTyr制药之前，Broadfoot女士曾担任Emerald Health Pharmaceuticals Inc.和Emerald Health Bioceuticals Inc.的首席财务官，负责为美国的制药和生物医药实体建立运营，如建立运营、公司治理、财务和会计、信息技术和投资者关系职能等。在加入Emerald Health之前，Broadfoot女士曾担任GW Pharmaceuticals的副总裁兼美国公司财务总监，其职责包括建立美国商业运营、监督信息技术以及实施与公司业务从英国转移到美国相关的美国上市公司财务和会计准则。在加入GW Pharmaceuticals之前，Broadfoot女士曾担任Vical Inc.的首席财务官，负责监督财务、投资者关系、制造、信息技术、人力资源以及BINCE Development。在此之前，Broadfoot女士曾在DJO Global，Inc.担任多个职位，最近担任财务副总裁，并在Ernst & Young LLP担任审计经理。Broadfoot女士担任生物技术公司Talphera，Inc.的董事会成员。She Previoly曾在Otonomy，Inc.和Angiocrine Biosciences，Inc.的董事会任职，这两家公司都是一家生物技术公司。
- Jill Broadfoot joined board of directors in June 2025. Ms. Broadfoot has served as Chief Financial Officer of aTyr Pharma, Inc., a clinical stage biopharmaceutical company, since July 2018. Prior to aTyr Pharma, Ms. Broadfoot served as Chief Financial Officer of Emerald Health Pharmaceuticals Inc. and Emerald Health Bioceuticals Inc., where she was responsible for establishing operations for the U.S. based pharmaceutical and bioceutical entities as ll as the establishment of operations, corporate governance, finance and accounting, information technology and investor relations functions, among others. Prior to Emerald Health, Ms. Broadfoot served as Vice President, U.S. Corporate Controller at GW Pharmaceuticals, where her responsibilities included establishing U.S. commercial operations, overseeing information technology, and implementing U.S. public company financial and accounting standards in connection with the transfer of corporate operations from the U.K. to the U.S. Prior to joining GW Pharmaceuticals, Ms. Broadfoot served as Chief Financial Officer of Vical Inc. where she had oversight of finance, investor relations, manufacturing, information technology, human resces, and biness development. Prior to that, Ms. Broadfoot held vario positions at DJO Global, Inc., most recently as Vice President of Finance, and served as an audit manager at Ernst & Young LLP. Ms. Broadfoot serves on the board of directors of Talphera, Inc., a biotechnology company. She previoly served on the board of directors of Otonomy, Inc. and Angiocrine Biosciences, Inc., both biotechnology companies.
- Usman Azam
-
Usman Azam，于2023年3月至2025年5月担任Inspirna，Inc.的首席执行官，Inspirna，Inc.是一家临床阶段的生物制药公司，专注于新型癌症药物的发现和开发。从2022年1月到2023年2月，阿扎姆博士担任基因工程公司Empyrean Neuroscience，Inc.的首席执行官。2016年12月至2022年1月，他担任Tmunity Therapeutics，Inc.的总裁兼首席执行官，该公司是一家生物技术公司，于2023年被吉利德旗下公司Kite Pharma收购。在加入Tmunity之前，Azam博士曾在美国和瑞士担任多个高级研发领导职务，包括2009年3月至2016年11月在诺华担任细胞和基因疗法全球负责人。Azam博士在2008年4月至2009年3月期间担任NovAccel Therapeutics的首席执行官。阿扎姆博士在2007年1月至2008年4月期间担任Aspreva Pharmaceuticals的首席医疗官。Azam博士此前曾于2004年至2006年在强生任职，包括担任强生旗下公司Ethicon的首席医疗官。在其职业生涯的早期，阿扎姆博士曾在葛兰素史克和辉瑞担任领导职务。阿扎姆博士目前担任ProTgen，Inc.的董事会成员，ProTgen，Inc.是一家私营生物技术公司。阿扎姆博士在利物浦大学医学院获得医学博士学位，并在英国获得妇产科董事会认证。
Usman Azam has served as President and Chief Executive Officer and as a director since September 2025. Dr. Azam previoly served as Chief Executive Officer of Inspirna, Inc., a privately held clinical stage biopharmaceutical company foced on the discovery and development of novel cancer drugs, from March 2023 to September 2025. Prior to joining Inspirna, Dr. Azam served as Chief Executive Officer of Empyrean Neuroscience, a genetic engineering company advancing a pipeline of neuroactive compounds targeting disorders of the central nervo system, from January 2022 to March 2023. Previoly, he served as President and Chief Executive Officer of Tmunity Therapeutics, Inc., a biotechnology company acquired by Kite Pharma, a Gilead company, where he was involved in the development of genetically engineered CAR T cell therapies for solid tumor applications in cancer from December 2016 to January 2022. Dr. Azam also served in vario senior research and development leadership roles in the United States and Switzerland at Novartis AG, a pharmaceutical company, from 2009 to 2016, including as Global Head of the Cell and Gene Therapies unit, where he helped deliver and launch the first ever FDA approval for a CAR T cell therapy in hematologic cancers. Earlier in his career, Dr. Azam held leadership roles across both innovative biotechnology and large pharmaceutical companies, including Pfizer Pharmaceuticals, Aspreva Pharmaceuticals, Johnson & Johnson, and GlaxoSmithKline (GSK). Dr. Azam received his M.D. from the University of Liverpool School of Medicine and is board certified in obstetrics and gynecology in the United Kingdom. - Usman Azam，于2023年3月至2025年5月担任Inspirna，Inc.的首席执行官，Inspirna，Inc.是一家临床阶段的生物制药公司，专注于新型癌症药物的发现和开发。从2022年1月到2023年2月，阿扎姆博士担任基因工程公司Empyrean Neuroscience，Inc.的首席执行官。2016年12月至2022年1月，他担任Tmunity Therapeutics，Inc.的总裁兼首席执行官，该公司是一家生物技术公司，于2023年被吉利德旗下公司Kite Pharma收购。在加入Tmunity之前，Azam博士曾在美国和瑞士担任多个高级研发领导职务，包括2009年3月至2016年11月在诺华担任细胞和基因疗法全球负责人。Azam博士在2008年4月至2009年3月期间担任NovAccel Therapeutics的首席执行官。阿扎姆博士在2007年1月至2008年4月期间担任Aspreva Pharmaceuticals的首席医疗官。Azam博士此前曾于2004年至2006年在强生任职，包括担任强生旗下公司Ethicon的首席医疗官。在其职业生涯的早期，阿扎姆博士曾在葛兰素史克和辉瑞担任领导职务。阿扎姆博士目前担任ProTgen，Inc.的董事会成员，ProTgen，Inc.是一家私营生物技术公司。阿扎姆博士在利物浦大学医学院获得医学博士学位，并在英国获得妇产科董事会认证。
- Usman Azam has served as President and Chief Executive Officer and as a director since September 2025. Dr. Azam previoly served as Chief Executive Officer of Inspirna, Inc., a privately held clinical stage biopharmaceutical company foced on the discovery and development of novel cancer drugs, from March 2023 to September 2025. Prior to joining Inspirna, Dr. Azam served as Chief Executive Officer of Empyrean Neuroscience, a genetic engineering company advancing a pipeline of neuroactive compounds targeting disorders of the central nervo system, from January 2022 to March 2023. Previoly, he served as President and Chief Executive Officer of Tmunity Therapeutics, Inc., a biotechnology company acquired by Kite Pharma, a Gilead company, where he was involved in the development of genetically engineered CAR T cell therapies for solid tumor applications in cancer from December 2016 to January 2022. Dr. Azam also served in vario senior research and development leadership roles in the United States and Switzerland at Novartis AG, a pharmaceutical company, from 2009 to 2016, including as Global Head of the Cell and Gene Therapies unit, where he helped deliver and launch the first ever FDA approval for a CAR T cell therapy in hematologic cancers. Earlier in his career, Dr. Azam held leadership roles across both innovative biotechnology and large pharmaceutical companies, including Pfizer Pharmaceuticals, Aspreva Pharmaceuticals, Johnson & Johnson, and GlaxoSmithKline (GSK). Dr. Azam received his M.D. from the University of Liverpool School of Medicine and is board certified in obstetrics and gynecology in the United Kingdom.
高管简历
中英对照 | 中文 | 英文- Colin G. Sandercock
ColinG.Sandercock自2017年12月4日起担任我们的高级副总裁，总法律顾问兼秘书。加入Cue Biopharma公司之前，他曾担任Perkins Coie LLP的合伙人（2010年7月以来），从事专利诉讼、采购、国内外专利组合的管理和执行、许可纠纷、商标纠纷，以及与侵权、有效性和运营自由有关的意见。Sandercock先生拥有摩拉维亚学院（Moravian College）的学士学位，宾夕法尼亚大学（University of Pennsylvania）的硕士学位和哥伦布法学院（Columbus School of Law）天主教大学（Catholic University）的法学博士学位。
Colin G. Sandercock has been Senior Vice President, General Counsel and Secretary since December 2017. Prior to joining Cue Biopharma, he was a partner at Perkins Coie LLP from July 2010 to December 2017, practicing in the areas of patent litigation, procurement, management and enforcement of domestic and foreign patent portfolio, licensing disputes, trademark disputes, and opinions relating to infringement, validity and freedom to operate. Mr. Sandercock holds a B.S. in Chemistry and Mathematics from Moravian College, a Materials Science & Engineering (M.S.E.) degree in Chemical and Biochemical Engineering from the University of Pennsylvania and a J.D. from Catholic University, Columb School of Law.- ColinG.Sandercock自2017年12月4日起担任我们的高级副总裁，总法律顾问兼秘书。加入Cue Biopharma公司之前，他曾担任Perkins Coie LLP的合伙人（2010年7月以来），从事专利诉讼、采购、国内外专利组合的管理和执行、许可纠纷、商标纠纷，以及与侵权、有效性和运营自由有关的意见。Sandercock先生拥有摩拉维亚学院（Moravian College）的学士学位，宾夕法尼亚大学（University of Pennsylvania）的硕士学位和哥伦布法学院（Columbus School of Law）天主教大学（Catholic University）的法学博士学位。
- Colin G. Sandercock has been Senior Vice President, General Counsel and Secretary since December 2017. Prior to joining Cue Biopharma, he was a partner at Perkins Coie LLP from July 2010 to December 2017, practicing in the areas of patent litigation, procurement, management and enforcement of domestic and foreign patent portfolio, licensing disputes, trademark disputes, and opinions relating to infringement, validity and freedom to operate. Mr. Sandercock holds a B.S. in Chemistry and Mathematics from Moravian College, a Materials Science & Engineering (M.S.E.) degree in Chemical and Biochemical Engineering from the University of Pennsylvania and a J.D. from Catholic University, Columb School of Law.
- Lucinda Warren
Lucinda Warren，在制药和生物技术领域拥有超过30年的全球经验。在加入Cue生物制药之前，她曾于2014年至2024年在医疗保健产品公司强生担任神经科学和日本区域业务发展副总裁，负责端到端业务发展，包括许可、并购和联盟管理。她的领导在优化资源、培养高绩效团队以及培养与利益相关者的牢固关系方面发挥了重要作用。Warren女士的丰富经验还包括在Janssen Cilag Australia和Janssen Biologics担任重要职务，在那里她领导业务部门并管理全球转型，通过战略交易持续提供价值。她目前在国际学校服务和战略联盟专业人员协会的董事会任职，贡献了她在金融和治理方面的专业知识。Warren女士拥有阿尔伯塔大学生物科学学士学位，辅修神经学。
Lucinda Warren has been Chief Financial and Biness Officer since February 2026. Prior to that, she served as Chief Biness Officer from September 2024 until February 2026. She has over 30 years of global experience in the pharmaceutical and biotechnology sectors. Prior to joining Cue Biopharma, she served as vice president of biness development for Neuroscience and Japan Regionally at Johnson & Johnson, a healthcare products company, from 2014 to 2024, where she was responsible for end to end biness development, including licensing, mergers and acquisitions, and alliance management. Ms. Warren previoly held significant roles at Janssen Cilag Atralia and Janssen Biologics, where she led biness units and managed global transitions.- Lucinda Warren，在制药和生物技术领域拥有超过30年的全球经验。在加入Cue生物制药之前，她曾于2014年至2024年在医疗保健产品公司强生担任神经科学和日本区域业务发展副总裁，负责端到端业务发展，包括许可、并购和联盟管理。她的领导在优化资源、培养高绩效团队以及培养与利益相关者的牢固关系方面发挥了重要作用。Warren女士的丰富经验还包括在Janssen Cilag Australia和Janssen Biologics担任重要职务，在那里她领导业务部门并管理全球转型，通过战略交易持续提供价值。她目前在国际学校服务和战略联盟专业人员协会的董事会任职，贡献了她在金融和治理方面的专业知识。Warren女士拥有阿尔伯塔大学生物科学学士学位，辅修神经学。
- Lucinda Warren has been Chief Financial and Biness Officer since February 2026. Prior to that, she served as Chief Biness Officer from September 2024 until February 2026. She has over 30 years of global experience in the pharmaceutical and biotechnology sectors. Prior to joining Cue Biopharma, she served as vice president of biness development for Neuroscience and Japan Regionally at Johnson & Johnson, a healthcare products company, from 2014 to 2024, where she was responsible for end to end biness development, including licensing, mergers and acquisitions, and alliance management. Ms. Warren previoly held significant roles at Janssen Cilag Atralia and Janssen Biologics, where she led biness units and managed global transitions.
- Daniel G. Baker
Daniel G. Baker，在制药行业拥有超过20年的药物开发经验。贝克博士是生物技术公司Kira Therapeutics的创始人，自2019年起担任该公司的首席执行官。他还曾在2022年4月至2024年10月期间担任上市生物技术公司Galapagos NV的董事会执行董事。2000年至2019年，他在强生的Janssen/Centocor部门担任免疫学研发副总裁，该部门现在是强生创新药的一部分，他的职责包括Remicade、Simponi和Stelara的临床开发，以及其他主要的临床药物项目。他对多个疾病领域的众多1至3期临床试验的监督和监督导致在美国、欧洲和日本获得超过15项监管批准。2015年，贝克博士担任疾病领域Stronghold Leader的角色，负责风湿病产品的2期和3期临床试验开发计划以及风湿病和免疫学的整体组合战略。贝克博士在宾夕法尼亚大学获得医学博士学位。他在宾夕法尼亚州立健康Milton S. Hershey医疗中心完成了住院医师实习，并在宾夕法尼亚大学完成了风湿病学和免疫学研究金，随后在麻省总医院完成了风湿病学研究奖学金。
Daniel G. Baker has been Interim Chief Development Officer since November 2024. Dr. Baker has over 20 years of drug development experience in the pharmaceutical indtry. Dr. Baker is the founder of Kira Therapeutics, a biotechnology company, where he has served as Chief Executive Officer since 2019. He also served as an Executive Director on the board of Galapagos NV, a publicly traded biotechnology company, from April 2022 until October 2024. From 2000 to 2019, he served as Vice President, Immunology R&D at Johnson & Johnson's Janssen/Centocor division, which is now part of Johnson & Johnson Innovative Medicine, where his responsibilities included clinical development of Remicade, Simponi and Stelara, as ll as other major clinical drug programs. His supervision and oversight of numero Phase 1 to 3 clinical trials in multiple disease areas led to more than 15 regulatory approvals in the U.S., Europe and Japan. In 2015, Dr. Baker assumed the role of Disease Area Stronghold Leader, where he was responsible for Phase 2 and 3 clinical trial development plans for rheumatology products and the overall portfolio strategy in rheumatology and immunology.- Daniel G. Baker，在制药行业拥有超过20年的药物开发经验。贝克博士是生物技术公司Kira Therapeutics的创始人，自2019年起担任该公司的首席执行官。他还曾在2022年4月至2024年10月期间担任上市生物技术公司Galapagos NV的董事会执行董事。2000年至2019年，他在强生的Janssen/Centocor部门担任免疫学研发副总裁，该部门现在是强生创新药的一部分，他的职责包括Remicade、Simponi和Stelara的临床开发，以及其他主要的临床药物项目。他对多个疾病领域的众多1至3期临床试验的监督和监督导致在美国、欧洲和日本获得超过15项监管批准。2015年，贝克博士担任疾病领域Stronghold Leader的角色，负责风湿病产品的2期和3期临床试验开发计划以及风湿病和免疫学的整体组合战略。贝克博士在宾夕法尼亚大学获得医学博士学位。他在宾夕法尼亚州立健康Milton S. Hershey医疗中心完成了住院医师实习，并在宾夕法尼亚大学完成了风湿病学和免疫学研究金，随后在麻省总医院完成了风湿病学研究奖学金。
- Daniel G. Baker has been Interim Chief Development Officer since November 2024. Dr. Baker has over 20 years of drug development experience in the pharmaceutical indtry. Dr. Baker is the founder of Kira Therapeutics, a biotechnology company, where he has served as Chief Executive Officer since 2019. He also served as an Executive Director on the board of Galapagos NV, a publicly traded biotechnology company, from April 2022 until October 2024. From 2000 to 2019, he served as Vice President, Immunology R&D at Johnson & Johnson's Janssen/Centocor division, which is now part of Johnson & Johnson Innovative Medicine, where his responsibilities included clinical development of Remicade, Simponi and Stelara, as ll as other major clinical drug programs. His supervision and oversight of numero Phase 1 to 3 clinical trials in multiple disease areas led to more than 15 regulatory approvals in the U.S., Europe and Japan. In 2015, Dr. Baker assumed the role of Disease Area Stronghold Leader, where he was responsible for Phase 2 and 3 clinical trial development plans for rheumatology products and the overall portfolio strategy in rheumatology and immunology.
- Usman Azam
Usman Azam，于2023年3月至2025年5月担任Inspirna，Inc.的首席执行官，Inspirna，Inc.是一家临床阶段的生物制药公司，专注于新型癌症药物的发现和开发。从2022年1月到2023年2月，阿扎姆博士担任基因工程公司Empyrean Neuroscience，Inc.的首席执行官。2016年12月至2022年1月，他担任Tmunity Therapeutics，Inc.的总裁兼首席执行官，该公司是一家生物技术公司，于2023年被吉利德旗下公司Kite Pharma收购。在加入Tmunity之前，Azam博士曾在美国和瑞士担任多个高级研发领导职务，包括2009年3月至2016年11月在诺华担任细胞和基因疗法全球负责人。Azam博士在2008年4月至2009年3月期间担任NovAccel Therapeutics的首席执行官。阿扎姆博士在2007年1月至2008年4月期间担任Aspreva Pharmaceuticals的首席医疗官。Azam博士此前曾于2004年至2006年在强生任职，包括担任强生旗下公司Ethicon的首席医疗官。在其职业生涯的早期，阿扎姆博士曾在葛兰素史克和辉瑞担任领导职务。阿扎姆博士目前担任ProTgen，Inc.的董事会成员，ProTgen，Inc.是一家私营生物技术公司。阿扎姆博士在利物浦大学医学院获得医学博士学位，并在英国获得妇产科董事会认证。
Usman Azam has served as President and Chief Executive Officer and as a director since September 2025. Dr. Azam previoly served as Chief Executive Officer of Inspirna, Inc., a privately held clinical stage biopharmaceutical company foced on the discovery and development of novel cancer drugs, from March 2023 to September 2025. Prior to joining Inspirna, Dr. Azam served as Chief Executive Officer of Empyrean Neuroscience, a genetic engineering company advancing a pipeline of neuroactive compounds targeting disorders of the central nervo system, from January 2022 to March 2023. Previoly, he served as President and Chief Executive Officer of Tmunity Therapeutics, Inc., a biotechnology company acquired by Kite Pharma, a Gilead company, where he was involved in the development of genetically engineered CAR T cell therapies for solid tumor applications in cancer from December 2016 to January 2022. Dr. Azam also served in vario senior research and development leadership roles in the United States and Switzerland at Novartis AG, a pharmaceutical company, from 2009 to 2016, including as Global Head of the Cell and Gene Therapies unit, where he helped deliver and launch the first ever FDA approval for a CAR T cell therapy in hematologic cancers. Earlier in his career, Dr. Azam held leadership roles across both innovative biotechnology and large pharmaceutical companies, including Pfizer Pharmaceuticals, Aspreva Pharmaceuticals, Johnson & Johnson, and GlaxoSmithKline (GSK). Dr. Azam received his M.D. from the University of Liverpool School of Medicine and is board certified in obstetrics and gynecology in the United Kingdom.- Usman Azam，于2023年3月至2025年5月担任Inspirna，Inc.的首席执行官，Inspirna，Inc.是一家临床阶段的生物制药公司，专注于新型癌症药物的发现和开发。从2022年1月到2023年2月，阿扎姆博士担任基因工程公司Empyrean Neuroscience，Inc.的首席执行官。2016年12月至2022年1月，他担任Tmunity Therapeutics，Inc.的总裁兼首席执行官，该公司是一家生物技术公司，于2023年被吉利德旗下公司Kite Pharma收购。在加入Tmunity之前，Azam博士曾在美国和瑞士担任多个高级研发领导职务，包括2009年3月至2016年11月在诺华担任细胞和基因疗法全球负责人。Azam博士在2008年4月至2009年3月期间担任NovAccel Therapeutics的首席执行官。阿扎姆博士在2007年1月至2008年4月期间担任Aspreva Pharmaceuticals的首席医疗官。Azam博士此前曾于2004年至2006年在强生任职，包括担任强生旗下公司Ethicon的首席医疗官。在其职业生涯的早期，阿扎姆博士曾在葛兰素史克和辉瑞担任领导职务。阿扎姆博士目前担任ProTgen，Inc.的董事会成员，ProTgen，Inc.是一家私营生物技术公司。阿扎姆博士在利物浦大学医学院获得医学博士学位，并在英国获得妇产科董事会认证。
- Usman Azam has served as President and Chief Executive Officer and as a director since September 2025. Dr. Azam previoly served as Chief Executive Officer of Inspirna, Inc., a privately held clinical stage biopharmaceutical company foced on the discovery and development of novel cancer drugs, from March 2023 to September 2025. Prior to joining Inspirna, Dr. Azam served as Chief Executive Officer of Empyrean Neuroscience, a genetic engineering company advancing a pipeline of neuroactive compounds targeting disorders of the central nervo system, from January 2022 to March 2023. Previoly, he served as President and Chief Executive Officer of Tmunity Therapeutics, Inc., a biotechnology company acquired by Kite Pharma, a Gilead company, where he was involved in the development of genetically engineered CAR T cell therapies for solid tumor applications in cancer from December 2016 to January 2022. Dr. Azam also served in vario senior research and development leadership roles in the United States and Switzerland at Novartis AG, a pharmaceutical company, from 2009 to 2016, including as Global Head of the Cell and Gene Therapies unit, where he helped deliver and launch the first ever FDA approval for a CAR T cell therapy in hematologic cancers. Earlier in his career, Dr. Azam held leadership roles across both innovative biotechnology and large pharmaceutical companies, including Pfizer Pharmaceuticals, Aspreva Pharmaceuticals, Johnson & Johnson, and GlaxoSmithKline (GSK). Dr. Azam received his M.D. from the University of Liverpool School of Medicine and is board certified in obstetrics and gynecology in the United Kingdom.